Welcome to our dedicated page for Can-Fite BioPharma Ltd. SEC filings (Ticker: CANF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Can-Fite BioPharma Ltd. filings document foreign-private-issuer disclosures for a clinical-stage biotechnology company whose American Depositary Shares trade under CANF. Its Form 6-K reports furnish press releases, annual and special meeting materials, proxy statements, voting instruction cards for ADS holders, and shareholder-vote results.
The company’s regulatory record covers clinical and regulatory updates for A3AR drug candidates, Namodenoson and Piclidenoson patent matters, partner-related development disclosures, operating and financial results, capital-structure items, registration-statement incorporation for Form S-8 and Form F-3 filings, governance matters, and risks connected to drug development and public-company financing.
Can-Fite BioPharma Ltd. furnished a report noting that it issued a press release titled “Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change.” The company states that this press release, dated December 23, 2025, is incorporated by reference into its existing Form S-8 and Form F-3 registration statements. The report is signed by Motti Farbstein, who serves as both Chief Executive Officer and Chief Financial Officer.
Can-Fite BioPharma Ltd. changed the terms of an existing warrant package covering 16,666,666 American Depositary Shares. On November 18, 2025, the company agreed with the warrant holder to lower the exercise price on these warrants from $0.60 per ADS to $0.467 per ADS. In exchange, the holder waived certain standstill provisions, which had limited its actions in relation to the company. This adjustment makes it cheaper for the holder to exercise the warrants while releasing the company from the prior standstill constraints.
Can-Fite BioPharma Ltd. submitted a Form 6-K noting that it has furnished a press release as Exhibit 99.1. The press release, dated November 20, 2025, announces that Can-Fite’s CF602 erectile dysfunction treatment has received a notice of patent allowance in Brazil. The first paragraph of this press release is incorporated by reference into several of the company’s existing Form S-8 and Form F-3 registration statements.
Can-Fite BioPharma Ltd. (CANF) submitted a Form 6-K to furnish a new press release about its liver cancer drug candidate Namodenoson. The filing states that the first paragraph of the press release is incorporated by reference into several existing Form S-8 and Form F-3 registration statements, meaning that key descriptive information about the company and its programs is now formally part of those documents. The press release, titled “Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson,” highlights an advanced liver cancer patient who achieved 9-year survival with a complete cure while being treated with Namodenoson. The Form 6-K itself does not provide additional clinical data or financial details beyond announcing and cross-referencing this communication.
Can-Fite BioPharma Ltd. reported that shareholders approved both proposals presented at its Special General Meeting on November 10, 2025. The proposals were described in the company’s Notice and Proxy Statement dated October 3, 2025, which was furnished as Exhibit 99.1 to a prior Form 6-K on October 3, 2025.
Can-Fite BioPharma Ltd. adjourned its Special General Meeting of Shareholders due to lack of quorum and will reconvene on Monday, November 10, 2025 at 3:00 p.m. (Israel time) at the company’s offices, 26 Ben Gurion Street, Ramat Gan, Israel.
Can-Fite BioPharma Ltd. furnished a Notice and Proxy Statement, a Proxy Card for ordinary shareholders, and a Voting Instruction Card for American Depositary Shareholders in connection with a Special General Meeting of Shareholders. The report is dated October 3, 2025 and is signed by Motti Farbstein, who is listed as Chief Executive Officer and Chief Financial Officer. The filing incorporates prior registration statements by reference to the extent not superseded.
Can-Fite BioPharma Ltd., an Israel-based foreign private issuer, submitted a Form 6-K to furnish a new press release and update its existing registration statements. The company reports that it issued a press release on September 15, 2025 titled “Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson,” describing a clinical outcome in a decompensated cirrhosis patient treated with its drug candidate Namodenoson.
The first paragraph of this press release is incorporated by reference into Can-Fite’s effective Form S-8 and Form F-3 registration statements, meaning the information in that paragraph is now formally part of those securities offering documents. The press release itself is attached to this report as Exhibit 99.1.
Can-Fite BioPharma Ltd., an Israel-based foreign private issuer, submitted a Form 6-K to furnish a new press release and update its existing registration statements. The company reports that it issued a press release on September 15, 2025 titled “Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson,” describing a clinical outcome in a decompensated cirrhosis patient treated with its drug candidate Namodenoson.
The first paragraph of this press release is incorporated by reference into Can-Fite’s effective Form S-8 and Form F-3 registration statements, meaning the information in that paragraph is now formally part of those securities offering documents. The press release itself is attached to this report as Exhibit 99.1.
Can-Fite BioPharma Ltd. filed a Form 6-K as a foreign private issuer to provide investors with its operating and financial review and unaudited interim condensed consolidated financial statements for the six months ended June 30, 2025. The company also issued a press release on that date summarizing its financial results for the period and giving updates on its drug development programs. The 6-K specifies that the financial review, interim financial statements, and portions of the press release are incorporated by reference into several existing Form S-8 and Form F-3 registration statements, allowing those registration statements to use the newly furnished information.